StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $17.92 | $17.15 | -4.30% | 2.7M |
| 05-08 | $17.46 | $18.08 | +3.55% | 3.9M |
| 05-11 | $18.21 | $18.66 | +2.47% | 4.2M |
| 05-12 | $18.30 | $18.95 | +3.55% | 2.2M |
| 05-13 | $18.81 | $18.79 | -0.11% | 2.2M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Each factor shows SMMT's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Press releases, AI summaries, and links to free transcript sources. Audio webcasts live on the issuer's IR site.
Press releases served direct from sec.gov. Stonvex doesn't host transcript bodies — these require the publisher's terms.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 |
|---|---|---|---|---|---|
Revenue | $144.33K | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | Not available | $-226.00M | $-160.38M | $-609.65M | $-573.44M |
Net Income | Not available | $-221.31M | $-160.11M | $-614.93M | $-578.36M |
EPS (Diluted) | $-0.29 | $-0.31 | $-0.22 | $-0.99 | $-0.98 |
Total Assets | Not available | $435.56M | $502.85M | $202.95M | $218.48M |
Total Liabilities | Not available | $46.81M | $64.93M | $125.26M | $119.10M |
Cash & Equivalents | Not available | $104.86M | $93.78M | $71.42M | $23.79M |
Free Cash Flow OCF − CapEx | Not available | $-142.25M | $-93.56M | $-76.89M | $-57.43M |
Shares Outstanding | Not available | 737.63M | 737.09M | 701.66M | 697.85M |
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
SMMT is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.
Quiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.